Ainos, Inc. announced critical progress in the clinical trials of its revolutionary ?Ainos Flora? volatile organic compound (?VOC?) POCT device that is based upon its transformative AI-powered digital nose (?AI Nose?) technology. Designed to provide rapid, non-invasive detection of bacterial, fungal, and certain common sexually transmitted infections (?STI?) in women, Ainos Flora has been in clinical trials at four major medical centers in Taiwan.

The trials have successfully tested 75 clinical cases with meaningful insights, laying a solid foundation for the development of next-generation Ainos Flora. The trials validate the effectiveness of the AI algorithm model, demonstrating improved recognition accuracy by incorporating more real-world data into the Ainos AI model. Reliability is ensured via comprehensive data standardization facilitated by advanced pre-processing data and environmental correction algorithms for overcoming individual and environmental variations.

Additionally, refined software and hardware designs have optimized Ainos Flora's sensing performance and have also mitigated impact from operational environment interference. Building upon the success of current trials and leveraging the implementation of NVIDIA CUDA, a parallel computing platform and programming model developed by NVIDIA for general computing on graphical processing units (?GPUs?) to accelerate deep learning, Ainos is now developing the next generation of the Ainos Flora device, expanding the test portfolio to include viral infection. In recognition of growing demand for decentralized healthcare solutions in home healthcare, the second-generation Ainos Flora will feature improvements that allow users to obtain accurate results quickly and easily without professional medical training, further optimized for at-home testing.

Software and hardware design and laboratory testing are expected to be completed by the third quarter of this year, with clinical trials planned to commence in the fourth quarter. The Company's ongoing efforts to synergistically unite advanced deep learning algorithms with medical devices demonstrate Ainos' relentless commitment to innovation in AI and medical technology. With over 50 approved and pending patents, Ainos is pioneering the AI Nose technology by seamlessly integrating AI deep learning with digital nose sensors for a new generation of rapid diagnostic tools designed for early, convenient and telehealth-friendly disease diagnosis and health monitoring.

This technology has become a core growth driver for the Company, whose name is a fusion of the words ?AI? and ?Nose?. The AI Nose technology platform uses an array of digital nose sensors to identify VOC signals in gases.

By utilizing NVIDIA CUDA, Ainos is positioned to accelerate deep learning model training further, delivering faster and more convenient medical services. The Company's VOC POCT device, Ainos Flora, won the 2021 iF's Medicine/Health Design Award. This compact, non-invasive device collects VOC samples near the patient's genital area, offering a rapid, private, and user-friendly testing experience.

This technology not only aids in swift diagnosis and treatment by healthcare professionals but also empowers individuals to manage their health proactively through remote self-monitoring.